Skedgel, C <br/><br/>
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.  [electronic resource] 

 -  Breast cancer research and treatment  Mar 2007 
 - 325-33 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Validation Study 
<br/><br/><label>ISSN: </label>0167-6806 
<br/><br/><label>Standard No.: </label>10.1007/s10549-006-9299-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anastrozole<br/>Androstadienes--administration & dosage<br/>Antineoplastic Agents, Hormonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--economics<br/>Aromatase Inhibitors--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant--adverse effects<br/>Cost-Benefit Analysis<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Drug Costs<br/>Female<br/>Humans<br/>Markov Chains<br/>Middle Aged<br/>Models, Economic<br/>Neoplasm Recurrence, Local--prevention & control<br/>Nitriles--administration & dosage<br/>Postmenopause<br/>Quality-Adjusted Life Years<br/>Tamoxifen--administration & dosage<br/>Treatment Outcome<br/>Triazoles--administration & dosage<br/>United States